Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 12 June, 2012

Summit Corporation PLC

Summit Corporation PLC : Summit achieves SMT C1...

Summit Corporation PLC : Summit achieves SMT C1100 Phase 1 dosing milestone that triggers milestone payment

Summit Corporation plc
('Summit' or 'the Company')


  • Trial moves to Multiple Dose stage  

  • Summit to Participate in Upcoming Industry Events 

Oxford, UK, 12 June 2012 - Summit (AIM: SUMM), a UK drug discovery company, today announced that it has successfully passed a milestone in the Phase 1 trial of SMT C1100 for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy ('DMD'), which triggered the final payment from a $1.5 million funding agreement with US-based DMD organisations.  

SMT C1100, an oral small molecule compound, is a potential disease-modifying drug that works by increasing, or upregulating, the amount of a naturally occurring protein called utrophin.  The Phase 1 dose-escalation study in healthy volunteers was initiated in May 2012 and will now progress to the stage where participants receive multiple doses.  Results from the trial are expected by the end of this year.

The Phase 1 trial is being supported by a group of US-based DMD organisations: the Muscular Dystrophy Association, Charley's Fund, Cure Duchenne, the Foundation to Eradicate Duchenne, Nash Avery Foundation and Parent Project Muscular Dystrophy.

"We are grateful for the continuing support from the DMD organisations as we make significant progress in the Phase 1 trial of SMT C1100," said Glyn Edwards, Chief Executive Officer of Summit.  "The funding will enable completion of the Phase 1 trial this year, after which we will seek an appropriate partner to advance SMT C1100 through proof-of-concept studies to ultimately bring this potential breakthrough therapy to patients with DMD."

The Company will be available for partnering discussions at the BIO International Convention June 18-21, 2012, in Boston, MA.  In addition, Summit will present at the Parent Project Muscular Dystrophy Annual Connect Conference June 28-July 1, 2012, in Fort Lauderdale, FL.

SMT C1100 is designed to upregulate and maintain the production of utrophin.  Utrophin is a protein that is highly expressed in regenerating muscle, but decreases as the muscle fibre matures and is eventually replaced by dystrophin, a protein that maintains the integrity and healthy function of muscles.  Patients with DMD are unable to make dystrophin, resulting in muscle fibre degeneration.  However, if utrophin is continually expressed in the mature muscle fibre, it can replace the function of dystrophin and thereby overcome the deficit in patients with DMD.  

This approach is expected to be a universal treatment for all DMD patients regardless of whether the disease was caused by an inherited or spontaneous genetic mutation.  Summit has demonstrated in non-clinical efficacy studies that SMT C1100 is capable of increasing utrophin to restore and maintain the healthy function of muscles.

- END -

For more information, please contact:

Glyn Edwards / Richard Pye
Tel: +44 (0)1235 443 939
Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång

Tel: +44 (0)203 205 7500
Hybridan LLP
(Joint broker)
Claire Louise Noyce / Deepak Reddy

Tel: +44 (0)207 947 4350
Peckwater PR
(Financial public relations, UK)
Tarquin Edwards

Tel: +44 (0)7879 458 364
MacDougall Biomedical Communications
(U.S. media contact)
Michelle Avery

Tel: +1 781-235-3060

Notes to Editors

About DMD  
Duchenne muscular dystrophy is a fatal genetic neuromuscular disorder that affects 1 in 3,500 boys with an estimated patient population of 50,000 in the developed world.  The disease is caused by defects in the gene required to make dystrophin, a protein, which maintains the integrity and healthy function of muscles.  One in three new cases are due to a spontaneous mutation where there is no familial history of the disease.  The progressive muscle wasting begins in early childhood and typically leads to death in the twenties due to cardiac and respiratory failure.  Currently there is no cure for the disease.

About Utrophin Upregulation
Utrophin is a naturally occurring protein that has a similar function to dystrophin. Utrophin is produced during foetal muscle development but is switched off in mature muscle fibres.  If its production could be switched back on, utrophin could act as a substitute for the missing dystrophin to maintain the healthy function of muscles.  One method of turning utrophin production back on is through pharmacological means.  Utrophin upregulation will be beneficial to all DMD patients regardless of their specific genetic mutation and is also expected to be complimentary to other therapeutic approaches in development.

About SMT C1100
Discovered and developed by scientists at Summit, SMT C1100 has demonstrated its potential as a disease-modifying drug in non-clinical efficacy studies.  SMT C1100 disengages normal utrophin control such that utrophin RNA and protein is made continually in muscle.  It has received orphan drug designation in the US and Europe.

About MDA Venture Philanthropy (MVP)
MVP is the Muscular Dystrophy Association's drug development program, which operates within MDA's translational research program.  MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases.  For more information, visit and follow MDA on Facebook ( and Twitter (@MDAnews).

About Charley's Fund, Cure Duchenne, Foundation to Eradicate Duchenne,
and Nash Avery Foundation
Charley's Fund (, Cure Duchenne (, Foundation to Eradicate Duchenne (, and Nash Avery Foundation ( are independent organisations devoted to developing treatments for Duchenne muscular dystrophy.  These groups, founded by parents of children with Duchenne, support the most promising research.

About Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy.  Our mission is to end Duchenne.  We accelerate research, raise our voices in Washington, demand optimal care for all young men, and educate the global community.  PPMD is headquartered in Middletown, Ohio with offices in Fort Lee, New Jersey.  For more information, visit

About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Summit Corporation PLC via Thomson Reuters ONE